Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
China's drug regulator accepts application for pimicotinib, a new treatment for a rare tumor.
Shanghai-based Abbisko Therapeutics announced that China's NMPA has accepted the New Drug Application for pimicotinib, a CSF-1R inhibitor for treating Tenosynovial Giant Cell Tumor (TGCT).
Clinical trials showed significant improvements in patient outcomes.
The drug received Priority Review, expected to expedite its approval process.
Merck has global commercial rights to pimicotinib.
10 Articles
El regulador de medicamentos de China acepta la solicitud para pimicotinib, un nuevo tratamiento para un tumor raro.